Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · RUBICON

RUBICON

HealthcarePharmaceuticals & Biotechnology₹27508 cr market cap
₹1722.30 ▲ +3.86% today As of 19 Nov 2026
52-week low ₹615.2052-week high ₹1860.60

-10.9% from the 52-week high · +169.6% above the low

Rubicon Research Ltd is a pharmaceutical research and development company engaged in drug development, contract research, and manufacturing. It provides end-to-end services to global pharmaceutical clients, from early-stage discovery to clinical trials and regulatory support. Its capabilities include formulation development, bioanalytical studies, and manufacturing of active pharmaceutical ingredients. The company leverages its scientific expertise to deliver innovative and reliable solutions to the healthcare industry.

The short version. RUBICON reported revenue of ₹576 crore for Sep 2026, up 39.8% from a year earlier. Net profit was ₹90 crore (up 66.7% year on year). Return on equity was 19.1% in Mar 2026. Promoter holding was 51.24% in Sep 2026, down 8.75 points over 5 quarters.

1 · The price

How has the stock traded?

RUBICON trades 10.9% below its 52-week high and 169.6% above its 52-week low.

Change over period: —

1M+11.5%
3M-7.8%
6M+68.2%
1Y+128.9%

2 · The business

Is it growing?

Sales, year on year+39.8%

Sep 2026 revenue of ₹576 cr.

Profit, year on year+66.7%

Sep 2026 net profit of ₹90 cr.

Net margin15.7%

2.6 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025
Revenue576534514476412
Net profit9085777354
Net margin %15.715.914.915.313.1
EPS (₹)5.475.134.654.423.27

Annual

FY2026
Revenue1754
Net profit247
Net margin %14.1
EPS (₹)14.95

3 · The quality

How well does it turn capital into profit?

Return on equity was 19.1% in Mar 2026; debt to equity is 0.20.

Profitability · 1 years

Returns and margins

Mar 2026
Return on equity %19.1
Return on capital %24.3
EBITDA margin %23.2
Net margin %14.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.20
Interest cover8.6x
Current ratio2.01
P/E ratio86.0

4 · The owners

Who holds it, and are they adding?

Promoter holding51.24%

Down 8.75 pts over 5 quarters.

Foreign institutions9.01%

Down 0.36 pts over 5 quarters.

Domestic institutions15.72%

Up 5.18 pts over 5 quarters.

Mutual fund schemes93

+29 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter59.9959.9959.8659.7651.24-8.75
FII9.377.997.547.529.01-0.36
DII10.549.4510.029.4315.72+5.18
Public20.122.5722.5823.324.02+3.92

Mutual fund holdings · Oct 2026

93 schemes hold this stock

64 the month before.

  • Bajaj Finserv Healthcare Fund5.84% of NAV
  • Kotak Manufacture In India Fund4.51% of NAV
  • MOTILAL OSWAL SMALL CAP FUND4.27% of NAV
  • Bajaj Finserv Small Cap Fund3.7% of NAV
  • ICICI Prudential Life Cycle Fund 20363.33% of NAV
  • CANARA ROBECO MANUFACTURING FUND3.24% of NAV
  • HDFC Innovation Fund3.19% of NAV
  • Motilal Oswal Focused Fund3.11% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for RUBICON are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about RUBICON

What is the RUBICON share price?

RUBICON (RUBICON) last closed at ₹1,722.30, up 3.86% on the day. Its 52-week range is ₹615.20 to ₹1,860.60.

What is the market cap of RUBICON?

RUBICON has a market capitalisation of about ₹27,508 crore. Its price-to-earnings ratio is 86.0.

How are RUBICON's latest results?

RUBICON reported revenue of ₹576 crore for Sep 2026, up 39.8% from a year earlier. Net profit was ₹90 crore (up 66.7% year on year). Return on equity was 19.1% in Mar 2026. Promoter holding was 51.24% in Sep 2026, down 8.75 points over 5 quarters.

Who owns RUBICON?

As of Sep 2026, shareholding was: Promoter 51.24%, FII 9.01%, DII 15.72%, Public 24.02%.

How many mutual funds hold RUBICON?

93 mutual fund schemes held RUBICON in October 2026. That compares with 64 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.